Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®)
暂无分享，去创建一个
C. Carlo-Stella | E. Seregni | E. Bombardieri | A. Coliva | M. Maccauro | C. Chiesa | A. Guidetti | F. Botta | M. Gianni | L. Devizzi | Emilio Bombardieri | Francesca Botta | Carmelo Carlo-Stella